Safety, tolerability., and pharmacologic activity of multiple doses of the new platelet activating factor antagonist WEB 2086 in human subjects-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety, tolerability., and pharmacologic activity of multiple doses of the new platelet activating factor antagonist WEB 2086 in human subjects

Published:1989-03 Issue:3 Volume:45 Page:270-276
ISSN:0009-9236
Container-title:Clinical Pharmacology and Therapeutics
language:
Short-container-title:Clin Pharmacol Ther

Author:

Adamus W S,Heuer H,Meade C J,Brecht H M

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interplay Between EGFR and the Platelet-Activating Factor/PAF Receptor Signaling Axis Mediates Aggressive Behavior of Cervical Cancer;Frontiers in Oncology;2020-12-17

2. Progress in the Development of Platelet-Activating Factor Receptor (PAFr) Antagonists and Applications in the Treatment of Inflammatory Diseases;ChemMedChem;2018-08-16

3. Potential Therapeutic Strategies for Severe Anaphylaxis Targeting Platelet-Activating Factor and PAF Acetylhydrolase;Current Treatment Options in Allergy;2014-05-15

4. Growth inhibition and differentiation of human breast cancer cells by the PAFR antagonist WEB-2086;British Journal of Cancer;2006-05-23

5. WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential;Leukemia;2005-01-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP